子宫癌药物及诊断市场－全球产业规模、份额、趋势、机会及预测（依癌症类型、药物、诊断、地区及竞争格局划分，2021-2031年）

全球子宫颈癌治疗和诊断市场预计将从 2025 年的 232.1 亿美元成长到 2031 年的 325.7 亿美元，复合年增长率为 5.81%。

该市场涵盖用于治疗子宫内膜癌和子宫肉瘤的药物、外科手术和诊断技术。其成长主要受肥胖和停经后妇女荷尔蒙失衡等风险因素增加以及政府改善医疗基础设施和推广早期筛检计画等措施的推动。

儘管存在这些积极因素，但先进免疫疗法和标靶药物递送系统的高成本仍然是获得治疗的一大障碍，尤其是在发展中地区。儘管疾病负担日益加重，但这项经济挑战依然存在：美国癌症协会估计，2024年美国将新增67,880例宫内膜癌病例。因此，与长期照护相关的经济限制仍然是市场进一步扩张的一大障碍。

市场驱动因素

推动市场成长的关键因素是新型标靶治疗和免疫疗法的快速监管核准，这些疗法正在重塑进行性子宫内膜癌的标准治疗方案。监管机构对免疫查核点抑制剂的核准不断增加；例如，基于一项纳入718名患者的DUO-E临床试验的结果，FDA于2024年6月核准Durvalumab联合化疗用于治疗错配修復缺陷型肿瘤。这些批准使製药公司能够将生物製药商业化，作为復发性疾病领域传统化疗的替代方案，从而刺激对肿瘤药物研发管线的进一步投资。

此外，由于人口老化和生活方式因素，全球子宫恶性肿瘤的发生率不断上升，因此亟需拓展诊断和治疗方法。这一成长趋势在国际上也十分明显。加拿大癌症协会于2024年5月发布的报告预测，该国每年新增子宫癌病例将达8,700例。这种日益增长的发病率带来了巨大的商业性回报，葛兰素史克(GSK)报告称，其子宫内膜癌治疗药物Gempari仅在2024年第三季度的销售额就达到了1.02亿英镑，便印证了这一点。

市场挑战

先进免疫疗法和标靶药物递送系统相关的巨额成本是限制子宫颈癌市场成长的主要因素。在医疗资源匮乏和医疗覆盖不足的地区，这些药物的高昂价格限制了病患的取得和使用，迫使医疗机构采用价格较低廉的传统疗法。这种经济障碍阻碍了新治疗通讯协定的广泛应用，从而降低了先进治疗药物生产商的获利潜力。

鑑于疾病的严重后果，在亟需有效介入的地区，这些经济限制的影响尤其显着。美国癌症协会预测，到2024年，子宫内膜癌将在美国造成约13,250人死亡，凸显了疾病的迫切临床需求。然而，长期治疗和新型药物方案的高昂费用持续阻碍市场渗透，导致临床需求与经济可行性之间持续存在差距，并减缓了该领域的整体商业性扩张。

市场趋势

针对HER2阳性疾病的抗体药物复合体（ADC）的兴起，标誌着子宫恶性肿瘤（尤其是浆液性癌）治疗领域的重要进展。为了支持这一趋势，FDA于2024年4月基于DESTINY-PanTumor02试验加速核准了famtrastuzumab deruxtecan-nxki上市，该试验显示其客观缓解率达51.4%。这种治疗方法透过抗体将细胞毒性药物直接递送至癌细胞，与传统疗法相比，可最大限度地降低全身毒性，并为已用尽标准疗法的患者提供了一种新的精准医疗选择。

同时，机器人辅助微创手术技术的兴起正在重新定义子宫切除术和分期手术的治疗标准。这些平台为外科医生提供了更佳的控制力和视野，这对于肥胖患者群体尤其重要，因为肥胖是该疾病的高发人群，同时也有助于减少术后併发症。直觉外科公司（Intuitive Surgical）2024年10月发布的报告也印证了人们对这项技术的日益依赖。报告显示，全球达文西手术系统手术量年增约18%，这将有助于医疗机构应对不断成长的患者群。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球子宫颈癌药物及诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 癌症类型（子宫内膜腺癌、腺鳞癌、乳头状浆液性癌、子宫肉瘤）
  • 依治疗方法（手术、免疫疗法、放射线治疗、化疗、其他）
  • 透过诊断方法（切片检查、骨盆超音波、子宫镜检查、刮除手术、 电脑断层扫描）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美子宫颈癌药物及诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲子宫颈癌药物及诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区子宫颈癌药物及诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东及非洲子宫颈癌药物及诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲子宫颈癌药物及诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球子宫癌药物及诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Uterine Cancer Therapeutics & Diagnostics Market is projected to expand from USD 23.21 Billion in 2025 to USD 32.57 Billion by 2031, registering a CAGR of 5.81%. This market includes pharmaceutical agents, surgical interventions, and diagnostic technologies aimed at managing endometrial cancer and uterine sarcoma. Growth is largely fueled by the increasing prevalence of risk factors such as obesity and hormonal imbalances in postmenopausal women, alongside government efforts to improve healthcare infrastructure and promote early screening programs.

Despite these positive drivers, the high cost of advanced immunotherapies and targeted drug delivery systems poses a major barrier to accessibility, particularly in developing regions. This economic challenge persists even as the disease burden grows; the American Cancer Society estimated that 67,880 new cases of uterine corpus cancer would be diagnosed in the United States in 2024. Consequently, financial constraints related to long-term care remain a significant impediment to the broader expansion of the market.

Market Driver

A primary engine for market growth is the accelerated regulatory approval of novel targeted therapies and immunotherapies, which are reshaping the standard of care for advanced endometrial carcinoma. Regulatory bodies are increasingly clearing immune checkpoint inhibitors, such as the FDA's June 2024 approval of durvalumab with chemotherapy for mismatch repair deficient tumors, a decision supported by the DUO-E clinical trial of 718 patients. These authorizations allow pharmaceutical developers to commercialize biologics that replace traditional chemotherapy in recurrent disease settings, incentivizing further investment in the oncology pipeline.

Additionally, the rising global incidence of uterine malignancies, driven by aging populations and lifestyle factors, necessitates an expansion of diagnostic and therapeutic availability. This growing burden is evident internationally, with the Canadian Cancer Society's May 2024 report projecting 8,700 new uterine cancer diagnoses in Canada for the year. This increasing prevalence translates into substantial commercial returns, as demonstrated by GSK's report that sales of the endometrial cancer treatment Jemperli reached £102 million in the third quarter of 2024 alone.

Market Challenge

The significant expense associated with advanced immunotherapies and targeted drug delivery systems acts as a major restraint on the uterine cancer market's growth. In areas with insufficient healthcare funding or limited insurance coverage, the high price of these agents restricts patient access and adoption, compelling healthcare providers to utilize older, less expensive alternatives. This economic barrier limits the widespread implementation of newer treatment protocols and subsequently reduces the revenue potential for manufacturers of advanced therapeutics.

These financial constraints are particularly impactful given the severe outcomes of the disease, which require effective intervention. The American Cancer Society projected approximately 13,250 deaths from uterine corpus cancer in the United States in 2024, highlighting the urgent clinical need. However, the prohibitive costs linked to long-term management and novel drug regimens continue to hinder market penetration, maintaining a gap between clinical requirements and economic feasibility that slows the sector's overall commercial expansion.

Market Trends

The rise of antibody-drug conjugates (ADCs) targeting HER2-positive disease represents a significant evolution in the management of uterine malignancies, especially serous carcinomas. Validating this trend, the FDA granted accelerated approval in April 2024 to fam-trastuzumab deruxtecan-nxki based on the DESTINY-PanTumor02 trial, which demonstrated an objective response rate of 51.4%. This approach delivers cytotoxic payloads directly to cancer cells via antibodies, minimizing systemic toxicity compared to traditional methods and offering a new precision medicine avenue for patients who have exhausted standard treatments.

Simultaneously, the adoption of robot-assisted minimally invasive surgical techniques is redefining the standard for hysterectomy and staging procedures. These platforms offer surgeons greater dexterity and visualization, which is particularly beneficial for the obese patient demographic often associated with this condition, while also reducing post-operative complications. The expanding reliance on this technology is underscored by Intuitive Surgical's October 2024 report, which noted an approximate 18% year-over-year growth in worldwide da Vinci procedures, supporting healthcare providers in managing increasing patient volumes.

Key Market Players

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

Report Scope

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type

• Endometrial Adenocarcinoma
• Adenosquamous Carcinoma
• Papillary Serous Carcinoma
• Uterine Sarcoma

Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics

• Surgery
• Immunotherapy
• Radiation Therapy
• Chemotherapy
• others

Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• Dilation and Curettage
• CT scan

Uterine Cancer Therapeutics & Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma)
  • 5.2.2. By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, others)
  • 5.2.3. By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By Diagnostics
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By Diagnostics
  • 6.3.2. Canada Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By Diagnostics
  • 6.3.3. Mexico Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By Diagnostics

7. Europe Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By Diagnostics
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By Diagnostics
  • 7.3.2. France Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By Diagnostics
  • 7.3.3. United Kingdom Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By Diagnostics
  • 7.3.4. Italy Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By Diagnostics
  • 7.3.5. Spain Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By Diagnostics

8. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By Diagnostics
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By Diagnostics
  • 8.3.2. India Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By Diagnostics
  • 8.3.3. Japan Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By Diagnostics
  • 8.3.4. South Korea Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapeutics
      • 8.3.4.2.3. By Diagnostics
  • 8.3.5. Australia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapeutics
      • 8.3.5.2.3. By Diagnostics

9. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By Diagnostics
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By Diagnostics
  • 9.3.2. UAE Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By Diagnostics
  • 9.3.3. South Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By Diagnostics

10. South America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By Diagnostics
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By Diagnostics
  • 10.3.2. Colombia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By Diagnostics
  • 10.3.3. Argentina Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By Diagnostics

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Uterine Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ariad Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Becton, Dickinson & Co.
• 15.4. GlaxoSmithKline Plc
• 15.5. Merck & Co., Inc.
• 15.6. Novartis AG
• 15.7. Sanofi SA
• 15.8. Siemens Healthineers AG.
• 15.9. F. Hoffmann-La Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer